Efficacy of oxaliplatin-based chemotherapy+bevacizumab as first-line treatment for advanced colorectal cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 38, Issue 2, 2015, Pages 227-233

  Petrelli, Fausto ^a   Coinu, Andrea ^a   Ghilardi, Mara ^a   Cabiddu, Mary ^a   Zaniboni, Alberto ^b   Barni, Sandro ^a  

^a TREVIGLIO HOSPITAL   (Italy)

^b Istituto ospedaliero Fondazione Poliambulanza di Brescia   (Italy)

Author keywords

bevacizumab; chemotherapy; colorectal cancer; first line; oxaliplatin; pooled analysis

Indexed keywords

BEVACIZUMAB; OXALIPLATIN; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; FLUOROURACIL; FOLINIC ACID; MONOCLONAL ANTIBODY; PLATINUM COMPLEX;

ADVANCED CANCER; CANCER COMBINATION CHEMOTHERAPY; COLORECTAL CANCER; COMORBIDITY; DRUG EFFICACY; HUMAN; METASTASIS RESECTION; OVERALL SURVIVAL; PATIENT SELECTION; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; COLORECTAL NEOPLASMS; PATHOLOGY;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; FLUOROURACIL; HUMANS; LEUCOVORIN; ORGANOPLATINUM COMPOUNDS;

EID: 84926300524     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e3182a2d7b8     Document Type: Review

References (30)

1. Macedo LT, da Costa Lima AB, Sasse AD. Addition of bevacizumab to first-line chemotherapy in advanced colorectal cancer: A systematic review and meta-analysis, with emphasis on chemotherapy subgroups. BMC Cancer. 2012;12:89.
2. Cassidy J, Clarke S, Díaz-Rubio E, et al. XELOX vs. FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results. Br J Cancer. 2011;105:58-64.
3. Hochster HS, Hart LL, Ramanathan RK, et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. J Clin Oncol. 2008;26: 3523-3529, Erratum in: J Clin Oncol 2008;26:4697.
4. Van Cutsem E, Rivera F, Berry S, et al. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: The BEAT study. Ann Oncol. 2009;20:1842-1847.
5. Kozloff M, Yood MU, Berlin J, et al. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: The BRiTE observational cohort study. Oncologist. 2009; 14:862-870.
6. Okines A, Puerto OD, Cunningham D, et al. Surgery with curativeintent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomized phase-III NO16966 trial. Br J Cancer. 2009;101:1033-1038.
7. Bendell JC, Bekaii-Saab TS, Cohn AL, et al. Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX-bevacizumab or FOLFIRI-bevacizumab: results from ARIES, a bevacizumab observational cohort study. Oncologist. 2012;17:1486-1495.
8. Hong YS, Lee SS, Kim KP, et al. A phase II study of bevacizumab, oxaliplatin, and capecitabine in patients with previously untreated metastatic colorectal cancer: A prospective, multicenter trial of the Korean Cancer Study Group. Am J Clin Oncol. 2012. [Epub ahead of print].
9. Rosati G, Avallone A, Aprile G, et al. XELOX and bevacizumab followed by single-agent bevacizumab as maintenance therapy as first-line treatment in elderly patients with advanced colorectal cancer: The boxe study. Cancer Chemother Pharmacol. 2013;71: 257-264.
10. Schmoll HJ, Cunningham D, Sobrero A, et al. Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: A doubleblind, randomized phase III study (HORIZON III). J Clin Oncol. 2012;30:3588-3595.
11. McCahill LE, Yothers G, Sharif S, et al. Primary mFOLFOX6 plus bevacizumab without resection of the primary tumor for patients presenting with surgically unresectable metastatic colon cancer and an intact asymptomatic colon cancer: definitive analysis of NSABP trial C-10. J Clin Oncol. 2012;30:3223-3228.
12. Hurwitz H, Mitchell EP, Cartwright T, et al. A randomized, phase II trial of standard triweekly compared with dose-dense biweekly capecitabine plus oxaliplatin plus bevacizumab as first-line treatment for metastatic colorectal cancer: XELOX-A-DVS (dense versus standard). Oncologist. 2012;17:937-946.
13. Díaz-Rubio E, Gómez-Espanã A, Massutí B, et al. First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: The phase III MACRO TTD study. Oncologist. 2012;17:15-25.
14. Meyerhardt JA, Li L, Sanoff HK, et al. Effectiveness of bevacizumab with first-line combination chemotherapy for Medicare patients with stage IV colorectal cancer. J Clin Oncol. 2012;30:608-615.
15. Saltz L, Badarinath S, Dakhil S, et al. Phase III trial of cetuximab, bevacizumab, and 5-fluorouracil/leucovorin vs. FOLFOX-bevacizumab in colorectal cancer. Clin Colorectal Cancer. 2012;11: 101-111.
16. Sehgal R, Lembersky BC, Rajasenan KK, et al. A phase I/II study of capecitabine given on a week on/week off schedule combined with bevacizumab and oxaliplatin for patients with untreated advanced colorectal cancer. Clin Colorectal Cancer. 2011;10: 117-120.
17. Wong NS, Fernando NH, Bendell JC, et al. A phase II study of oxaliplatin, dose-intense capecitabine, and high-dose bevacizumab in the treatment of metastatic colorectal cancer. Clin Colorectal Cancer. 2011;10:210-216.
18. Wong R, Cunningham D, Barbachano Y, et al. A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection. Ann Oncol. 2011;22: 2042-2048.
19. Madajewicz S, Waterhouse DM, Ritch PS, et al. Multicenter, randomized phase II trial of bevacizumab plus folinic acid, fluorouracil, gemcitabine (FFG) versus bevacizumab plus folinic acid, fluorouracil, oxaliplatin (FOLFOX4) as first-line therapy for patients with advanced colorectal cancer. Invest New Drugs. 2012;30:772-778.
20. Doi T, Boku N, Kato K, et al. Phase I/II study of capecitabine plus oxaliplatin (XELOX) plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer. Jpn J Clin Oncol. 2010;40:913-920.
21. Tol J, Koopman M, Cats A, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med. 2009;360:563-572, Erratum in: N Engl J Med. 2010 Dec 23;363:2573.
22. Hecht JR, Mitchell E, Chidiac T, et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol. 2009;27:672-680.
23. Gruenberger B, Tamandl D, Schueller J, et al. Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol. 2008;26:1830-1835.
24. Puthillath A, Dunn KB, Rajput A, et al. Safety and efficacy of first-line chemotherapy in unresected metastatic colorectal cancer. Clin Colorectal Cancer. 2007;6:710-715.
25. Bir A, Tan W, Wilding GE, et al. 5-fluorouracil, leucovorin and oxaliplatin plus bevacizumab in the first-line treatment of metastatic colorectal cancer: A single-institute study. Oncology. 2007;72:4-9.
26. Emmanouilides C, Sfakiotaki G, Androulakis N, et al. Front-line bevacizumab in combination with oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: A multicenter phase II study. BMC Cancer. 2007;7:91.
27. Vaidyanathan G, Groman A, Wilding G, et al. Stop and go FOLFOX plus bevacizumab chemotherapy in the first-line treatment of metastatic colorectal cancer. Oncology. 2010;79:67-71.
28. Cassidy J, Clarke S, Díaz-Rubio E, et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol. 2008;26:2006-2012.
29. Petrelli F, Barni S. Anti-EGFR agents for liver metastases. Resectability and outcome with anti-EGFR agents in patients with KRAS wild-type colorectal liver-limited metastases: A metaanalysis. Int J Colorectal Dis. 2012;27:997-1004.
30. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335.